



September 5, 2012

Over 350 Surgeons Register for Integra LifeSciences Workshops at the American Society for Surgery of the Hand (ASSH) Annual Meeting

PLAINSBORO, N.J., Sept. 5, 2012 (GLOBE NEWSWIRE) -- [Integra LifeSciences Holdings Corporation](#) (Nasdaq:IART) will offer three workshops at the 67th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on September 6-8, 2012 in Chicago, Illinois. Over 350 surgeons have signed up for the workshops, which will focus on nerve and soft tissue repairs, ulnar nerve decompression, and wrist arthritis.

The conference is expected to attract over 2,500 general, orthopedic and plastic hand surgeons, as well as several hundred executives from the small bone and joint market. The convention includes over 100 manufacturer and service provider booths.

"Integra is a proud Premier Partner of the ASSH meeting," said Robert D. Paltridge, President of Integra Extremity Reconstruction. "Our three educational workshops will provide surgeons with valuable insights in the use of our products, and how each can benefit their practice and offer additional clinical solutions for their patients."

Integra's exhibit (Booth #305) will also highlight other products, including the Integra[®] Total Wrist Fusion System, TenoGlide[®] Tendon Protector Sheet, PyroCarbon PIP and MCP Total Joint Replacements, First Choice[®] DRUJ Partial and Modular Ulnar Heads, and EndoRelease[™] Endoscopic Cubital Tunnel Release System.

Schedule of Integra sponsored ASSH Workshops:

Thursday, September 6, 2012

11:30-12:30pm

Location: Regency C

Industry Forum 12: Management of Challenging Nerve and Soft Tissue Injuries: Solutions for the Hand

Faculty: **Randip R. Bindra, MD FRCS** (*Professor, Orthopaedic Surgery, Loyola University Medical Center*) & **John T. Capo, MD** (*Professor, Department of Orthopaedics, New York University—Hospital for Joint Diseases*)

This workshop will focus on classic and new innovative techniques for management of complex hand soft tissue injuries in an interactive case discussion format. The use of intrinsic flaps and collagen templates will be discussed for managing soft tissue loss. Role of nerve entubulation repair and collagen wraps for nerve scarring will be highlighted using complex clinical cases with interactive participation from the audience.

Friday, September 7, 2012

7:00-8:00am

Location: Regency A

Industry Forum 24: Endoscopic Cubital Tunnel Release

Faculty: **Tyson Cobb, MD** (*Orthopaedic Specialists PC*)

This workshop will feature a presentation of published literature and outcomes for endoscopic cubital tunnel release. In addition, an examination of the clinical history of the procedure including the indications, contraindications, and complications will be discussed. Faculty will review the surgical technique and benefits of performing an endoscopic release with the EndoRelease[™] Endoscopic Cubital Tunnel System.

Friday, September 7, 2012

12:00-1:00pm

Location: Comiskey

Industry Forum 33: Advanced Wrist Arthritis - New Technologies for Treatment

Faculty: **Brian Adams, MD** (*Professor, University of Iowa, Department of Orthopedics and Rehabilitation*)

This workshop will focus on advanced wrist arthritis and present the newest technologies for treatment. By using a variety of techniques and implants, a surgeon can better match treatment to the patient's type of arthritis, physical demands, and desires. Among the techniques to be presented will be the Universal2™ Total Wrist Implant System as well as the First Choice® DRUJ, intended for partial replacement of the distal ulna, allowing the possibility of preservation of the ulnar styloid and TFCC attachments.

[Integra LifeSciences](http://www.integralife.com), a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

CONTACT: Integra LifeSciences Holdings Corporation

Gianna Sabella

Director, Corporate Communications

(609) 936-2389

gianna.sabella@integralife.com